Open Access

A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury

  • Authors:
    • Jing Liu
    • Qingshu Meng
    • Xiaoting Liang
    • Rulin Zhuang
    • Dongsheng Yuan
    • Xinyu Ge
    • Hao Cao
    • Fang Lin
    • Xin Gong
    • Huimin Fan
    • Binghui Wang
    • Xiaohui Zhou
    • Zhongmin Liu
  • View Affiliations

  • Published online on: November 27, 2019     https://doi.org/10.3892/ijmm.2019.4413
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Persistent ventricular remodeling following myocardial ischemia/reperfusion (MI/R) injury results in functional decompensation and eventual progression to heart failure. VCP979, a novel small‑molecule compound developed in‑house, possesses anti‑inflammatory and anti‑fibrotic activities. In the present study, no significant pathological effect was observed following the administration of VCP979 on multiple organs in mice and no difference of aspartate transaminase/alanine aminotransferase/lactate dehydrogenase levels was found in murine serum. Treatment with VCP979 ameliorated cardiac dysfunction, pathological myocardial fibrosis and hypertrophy in murine MI/R injury models. The administration of VCP979 also inhibited the infiltration of inflammatory cells and the pro‑inflammatory cytokine expression in hearts post MI/R injury. Further results revealed that the addition of VCP979 prevented the primary neonatal cardiac fibroblasts (NCFs) from Angiotensin II (Ang II)‑induced collagen synthesis and neonatal cardiac myocytes (NCMs) hypertrophy. In addition, VCP979 attenuated the activation of p38‑mitogen‑activated protein kinase in both Ang II‑induced NCFs and hearts subjected to MI/R injury. These findings indicated that the novel small‑molecule compound VCP979 can improve ventricular remodeling in murine hearts against MI/R injury, suggesting its potential therapeutic function in patients subjected to MI/R injury.

Related Articles

Journal Cover

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, J., Meng, Q., Liang, X., Zhuang, R., Yuan, D., Ge, X. ... Liu, Z. (1899). A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury. International Journal of Molecular Medicine, 0, 0-0. https://doi.org/10.3892/ijmm.2019.4413
MLA
Liu, J., Meng, Q., Liang, X., Zhuang, R., Yuan, D., Ge, X., Cao, H., Lin, F., Gong, X., Fan, H., Wang, B., Zhou, X., Liu, Z."A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury". International Journal of Molecular Medicine 0.0 (1899): 0-0.
Chicago
Liu, J., Meng, Q., Liang, X., Zhuang, R., Yuan, D., Ge, X., Cao, H., Lin, F., Gong, X., Fan, H., Wang, B., Zhou, X., Liu, Z."A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury". International Journal of Molecular Medicine 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ijmm.2019.4413